Back to Search
Start Over
Multiple myeloma, version 1.2013.
- Source :
-
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2013 Jan 01; Vol. 11 (1), pp. 11-7. - Publication Year :
- 2013
-
Abstract
- These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.
- Subjects :
- Antineoplastic Agents adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bendamustine Hydrochloride
Boronic Acids administration & dosage
Bortezomib
Dexamethasone administration & dosage
Disease Progression
Humans
Hydroxamic Acids administration & dosage
Lenalidomide
Multiple Myeloma complications
Nitrogen Mustard Compounds administration & dosage
Oligopeptides therapeutic use
Peripheral Nervous System Diseases etiology
Peripheral Nervous System Diseases therapy
Pyrazines administration & dosage
Recurrence
Thalidomide administration & dosage
Thalidomide analogs & derivatives
Vorinostat
Antineoplastic Agents therapeutic use
Multiple Myeloma drug therapy
Practice Guidelines as Topic
Salvage Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1540-1413
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of the National Comprehensive Cancer Network : JNCCN
- Publication Type :
- Academic Journal
- Accession number :
- 23307977
- Full Text :
- https://doi.org/10.6004/jnccn.2013.0004